AmpliPhi Biosciences Corp Form 3 January 31, 2017 UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 3 Washington, D.C. 20549 OMB

### **INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person <u>*</u> BILINSKY IGOR			<ul><li>2. Date of Event Requiring</li><li>Statement</li><li>(Month/Day/Year)</li></ul>	<sup>g</sup> 3. Issuer Name and Ticker or Trading Symbol AmpliPhi Biosciences Corp [APHB]		
(Last)	(First)	(Middle)	01/30/2017	4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)	
C/O AMPLIPHI BIOSCIENCES				(Check all applicable)		

Director

(give title below) (specify below)

Chief Operating Officer

\_X\_\_ Officer

## CORPORATION, 3579 VALLEY CENTRE DRIVE, **SUITE 100**

(Street)

## SAN DIEGO, CAÂ 92130

Table I - Non-Derivative Securities Beneficially Owned (City) (State) (Zip) 2. Amount of Securities 4. Nature of Indirect Beneficial 1.Title of Security 3. Beneficially Owned Ownership Ownership (Instr. 4) (Instr. 4) (Instr. 5) Form: Direct (D) or Indirect (I) (Instr. 5) Â Common Stock 0 D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

10% Owner

Other

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

#### Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security	2. Date Exercisable and	3. Title and Amount of	4.	5.	6. Nature of Indirect
(Instr. 4)	Expiration Date	Securities Underlying	Conversion	Ownership	Beneficial Ownership
	(Month/Day/Year)	Derivative Security	or Exercise	Form of	(Instr. 5)

**OMB APPROVAL** 

6. Individual or Joint/Group

Filing(Check Applicable Line) \_X\_ Form filed by One Reporting

Form filed by More than One

Person

Reporting Person

3235-0104 Number: January 31, Expires: 2005 Estimated average burden hours per response... 0.5

### Edgar Filing: AmpliPhi Biosciences Corp - Form 3

		(Instr. 4)		Price of	Derivative
Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative Security	Security: Direct (D) or Indirect (I) (Instr. 5)

# **Reporting Owners**

Reporting Owner Name / Address		Relationships				
	hepotenig of her function for		10% Owner	Officer	Other	
BILINSKY IGOR C/O AMPLIPHI BIOSCIENCES CORPORATION 3579 VALLEY CENTRE DRIVE, SUITE 100 SAN DIEGO, CA 92130		Â	Â	Chief Operating Officer	Â	
Signatures						
/s/ Igor P. Bilinsky	01/30/2017					
<u>**</u> Signature of Reporting Person	Date					
Evolopation	of Dooponoool					

# **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.